Emotional eating, after GLP-1

Semaglutide and tirzepatide switch off hunger. They don’t switch off the other reasons you eat when you aren’t hungry: the way food carries you from work to rest, the reward at the end of a brutal week, or the numbing of a feeling you’d rather not have. Those patterns survive the prescription. For some people, the medication is the first time they can see them clearly.

Here’s our position, up front. The medication opens a window. The physical drive to eat goes quiet, and the emotional patterns can become easier to see. For as long as you’re on the drug, you can rebuild habits without fighting hunger the whole way. The trials below show what happens to weight when the drug stops, but no trial shows what happens to the patterns. This guide is about that gap.

What the medication actually switches off

How these drugs work is well established. GLP-1 medications slow gastric emptying (how fast food leaves your stomach), act on the appetite centers in the brain, and help your body release insulin. Tirzepatide also acts on a second hormone, called GIP. Food stays in your stomach longer, and your brain’s drive to seek more of it drops. That’s the whole mechanism, and it’s enough:

• In STEP 1 (Wilding et al., NEJM 2021), 1,961 adults with obesity, or overweight plus a weight-related condition, and without diabetes took brand-name semaglutide (Wegovy) 2.4 mg weekly or a placebo. At week 68, the Wegovy group had lost 14.9% of their body weight on average, compared with 2.4% on placebo.
• In SURMOUNT-1 (Jastreboff et al., NEJM 2022), 2,539 adults took brand-name tirzepatide (Zepbound) for 72 weeks. Average weight loss on Zepbound was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, against 3.1% on placebo.

From the inside, the effect feels quieter than those numbers sound. Many people describe the constant background thinking about food going silent, sometimes before the scale has moved much. We’ve written about that separately as food noise.

But look at what those trials measured. The main endpoint was the change in body weight. They didn’t ask why anyone ate, or when, or what eating was doing for them emotionally, and on that question both trials are silent.

The eating that was never about hunger

The first time you feel sad and notice you aren’t hungry, it’s a strange moment. You wanted food, but your body didn’t. That difference is the key. Some people notice it more clearly on the medication, and some don’t.

Nothing in this section comes from a trial. These are common ways people describe eating when they aren’t hungry, offered to help you sort your own habits. Treat them as opinion and nothing stronger.

Here are three common patterns.

The bridge. You used food to get from one state to another: work to rest, awake to asleep, awkward to comfortable. You still have to make that shift, but the fridge has stopped calling to you. A walk does this job better than most people expect, and so does physically leaving the room where your workday ended.

The reward. You finished a hard week, and the celebration was a meal. The meal was never the problem. The problem was that it was the only thing on the list. Substitution works better here than anywhere else, because the point was always to mark the moment. The replacement has to feel like a real treat, so try a sauna, a long shower, a call to the friend who makes you laugh, or tickets to something. A salad is not a reward, and your brain knows it.

The numb. You ate so you wouldn’t have to feel something. This is the heaviest pattern, and the medication exposes it most, because the numbing is gone and nothing has replaced it. Therapy beats every food substitute here, so don’t try to engineer around it with walks and saunas. Eating may have been helping you cope with grief, trauma, or an anxiety disorder. If so, that condition needs its own treatment. An injection aimed at your appetite won’t provide it. We’ll say it plainly, even though we sell the injection: if numbing is most of your eating, a therapist is the right first prescription, and the medication can wait.

One firm rule while we’re here. A history of anorexia, bulimia, or binge eating disorder raises the risk of any appetite suppressant, so tell the reviewing clinician before your first dose. This is one of the few places where “talk to your doctor” is the actual advice.

What the regain trials showed

Two trials answer the question everyone eventually asks: what happens when I stop?

In STEP 4 (Rubino et al., JAMA 2021), everyone started on brand-name semaglutide (Wegovy), and at week 20 some participants were switched to placebo. The people who stopped regained a substantial amount of weight, while the people who continued kept their loss.

SURMOUNT-4 (Aronne et al., JAMA 2024) asked the same question about brand-name tirzepatide (Zepbound) with a longer lead-in, and it put numbers on the answer. After 36 weeks on Zepbound, those switched to placebo regained about 14% of their body weight over the next year. Those who stayed on Zepbound lost about 5.5% more.

The plain conclusion is that you keep the weight off by staying on the drug, and stopping usually reverses the loss. Nothing in those regain curves suggests the medication permanently resets your appetite. It holds the drive to eat down while it’s in your body, and when the drug leaves, the drive comes back.

There are two ways to read this. One is expert consensus, and the other is ours.

The consensus reading is that obesity behaves like a chronic condition, and staying on medication long term is legitimate treatment rather than failure. The strongest supporting data comes from SELECT (Lincoff et al., NEJM 2023), a trial of Wegovy. It enrolled 17,604 adults with overweight or obesity and established heart disease. None of them had diabetes. Brand-name semaglutide (Wegovy) 2.4 mg reduced major cardiovascular events, such as heart attack and stroke, by 20% in relative terms (hazard ratio 0.80). There are two caveats. That’s a relative number, and it comes from people who already had heart disease, so it doesn’t automatically apply to a 34-year-old with a BMI of 31 and clean arteries.

Our reading adds one thing. Even if you plan to stay on the drug indefinitely, treat the quiet as a time to build. People stop these medications for all kinds of reasons, including cost, supply, pregnancy, surgery, and simple preference. STEP 4 (brand-name semaglutide, Wegovy) and SURMOUNT-4 (brand-name tirzepatide, Zepbound) tell you the hunger will be waiting when you do. Whether the old patterns are also waiting depends on what you built while things were quiet. That last sentence is our clinical view rather than a trial result, because no trial has measured it.

The opposite problem: barely eating

When your appetite goes quiet, a new problem can appear that the old you never had. You may eat too little, and too little of what matters.

DXA substudies of the GLP-1 trials used body-composition scans on a subset of participants. They show that a meaningful share of the weight lost on these drugs is lean mass (mostly muscle) as well as fat. That evidence is real but incomplete. What it means for strength, mobility, or fracture risk at five or ten years hasn’t been studied. We don’t know. Anyone who tells you otherwise is guessing.

The standard countermeasure isn’t glamorous: resistance training, plus 1.2–1.6 g of protein per kilogram of body weight per day, which is the range clinicians commonly target. For an 80 kg person, that’s roughly 95–130 g of protein a day, and it takes deliberate planning when you’re never hungry. Eat protein first at every meal you do eat, and treat lifting as part of the prescription.

Dosing matters here too. Semaglutide titration (raising the dose a little at a time) usually starts at 0.25 mg weekly and steps up about every 4 weeks: 0.25, 0.5, 1.0, 1.7, 2.4 mg. It goes slower if side effects demand it. In STEP 1, which tested brand-name semaglutide (Wegovy), nausea was the most common side effect, and it clustered during dose increases. There’s a reason for that. The appetite effect and the queasiness both come from the same slowed gastric emptying, and each dose step slows it further. That’s why nausea usually eases once the dose stops climbing.

That leads to two practical points:

• Early nausea can look like progress. Not eating because you feel sick is different from not eating because the food noise stopped, and it tells you nothing about your emotional patterns. Wait until you’re on a steady dose before you judge how much work is left.
• If nausea is keeping you from getting protein in at all, or you can’t keep fluids down, talk to your clinician that same week about slowing the titration. The schedule is built to bend for exactly this. Persistent vomiting means stop and call, so don’t try to push through it.

What to do this week

Here’s the order we suggest:

1. Notice without fixing. For two weeks, when you reach for food without being hungry, don’t stop yourself. Just log it.
2. Keep a one-line journal. “Sad. Not hungry. Ate anyway.” Write the feeling, whether you were hungry, and whether you ate. It takes ten seconds.
3. Name your main pattern. After two weeks, the log usually reads like a diagnosis: mostly bridge, mostly reward, or mostly numb.
4. Act on the pattern instead of relying on willpower. For bridge or reward, pick one substitute and try it once this week. For numb, book a therapy appointment, because the substitutes won’t hold.
5. Eat protein on purpose at whatever meals you do eat.

Keep the sources straight. The drug effects and the regain numbers come from trials, and the protein range is standard clinical practice. The five steps above are our opinion and have never been tested in a randomized trial. If someone runs a good trial of a better sequence, we’ll swap ours for theirs.

Where Zappy fits

Zappy is cash-pay, so no insurance is required, and FSA and HSA funds are eligible. Zappy offers brand-name Wegovy, the Wegovy pill, and Zepbound, which are FDA-approved. It also offers compounded semaglutide and tirzepatide prepared by LegitScript-verified 503A pharmacies in the U.S. Compounded medications are not FDA-approved, and you should know that before choosing one. A U.S.-licensed clinician reviews every case and manages your titration, including slowing it down when nausea calls for it. If you’re still deciding whether medication fits your situation at all, start with the five-minute quiz.

The trial nobody has run

STEP 4 and SURMOUNT-4, the stopping trials for Wegovy and Zepbound, tested exactly one variable: drug or no drug. They tell us the average person regains weight without it. They don’t tell us whether that curve bends for people who used the window to do the work in this guide, such as naming their patterns, building substitutes, and treating the numbing with therapy instead of food. In the published discontinuation trials, that hasn’t been measured.

So here are the open questions we’re watching. Does structured behavioral treatment added to a GLP-1 change what happens after people stop? And does the lean mass lost on these drugs affect how people function ten years later? Nobody has either answer yet.

The medication gives you the window, and the work happens inside it. What no one has measured is how much of that work lasts after the window closes, and that’s the number we most want to see.